Basilea Raises FY26 Outlook As H1 Profit Soars; Stock Up

Basilea Pharmaceutica reports first-half 2026 profit of 27.95 million Swiss francs versus 15.80 million Swiss francs a year ago, with revenue up by 14.5% to 119.